Company Name: Cellectis S.A.
Cellectis is engaged in gene editing. The company develops immune-oncology products based on gene edited Chimeric Antigen Receptors (CAR) T-cells.
Ticker Symbol: CLLS (NASDAQ)
Company Website: www.cellectis.com
Social Media:
Headquarters: Paris, France
